{"id":"NCT00945945","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Duloxetine in Patients With Osteoarthritis Knee Pain","officialTitle":"A Phase 3b Study to Assess the Efficacy of Duloxetine 60 mg Once Daily Compared With Placebo on the Reduction of Pain Caused by Osteoarthritis of the Knee, in a 13-week, Double-blind, Randomized Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2009-07-24","resultsPosted":"2011-03-08","lastUpdate":"2011-03-08"},"enrollment":424,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Osteoarthritis Knee Pain"],"interventions":[{"type":"DRUG","name":"Duloxetine (DLX)","otherNames":["LY248686","Cymbalta"]},{"type":"DRUG","name":"Placebo (PLA)","otherNames":[]}],"arms":[{"label":"DLX30-PLA","type":"EXPERIMENTAL"},{"label":"PLA-DLX60","type":"PLACEBO_COMPARATOR"}],"summary":"The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.","primaryOutcome":{"measure":"Change From Baseline to 13 Week Endpoint (Baseline Observation Carried Forward [BOCF]) in Brief Pain Inventory (BPI) \"24-Hour Average Pain\" Item (Question 3) of the BPI-Modified Short Form Score","timeFrame":"Baseline, 13 weeks","effectByArm":[{"arm":"DLX30-PLA","deltaMin":6,"sd":1.28},{"arm":"PLA-DLX60","deltaMin":6.1,"sd":1.31}],"pValues":[{"comp":"OG000 vs OG001","p":"0.105"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":25},"locations":{"siteCount":26,"countries":["United States","Germany","Greece","Puerto Rico","Romania","Russia","Spain","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":207},"commonTop":["Nausea","Headache","Dizziness","Dry mouth","Diarrhoea"]}}